

Salvatore Cisternino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1677131/publications.pdf>

Version: 2024-02-01

103
papers

2,872
citations

172386

29
h-index

189801

50
g-index

111
all docs

111
docs citations

111
times ranked

3554
citing authors

#	ARTICLE	IF	CITATIONS
1	Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier. <i>Cancer Research</i> , 2004, 64, 3296-3301.	0.4	297
2	Deletion of Astroglial Connexins Weakens the Blood-Brain Barrier. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1457-1467.	2.4	185
3	A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. <i>Brain Research</i> , 2007, 1150, 1-13.	1.1	140
4	Evidence for an active transport of morphine-6- β -D-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. <i>Journal of Neurochemistry</i> , 2003, 86, 1564-1567.	2.1	129
5	Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. <i>British Journal of Pharmacology</i> , 2003, 138, 1367-1375.	2.7	105
6	ABCG2- and ABCG4-Mediated Efflux of Amyloid- β Peptide 1-40 at the Mouse Blood-Brain Barrier. <i>Journal of Alzheimer's Disease</i> , 2012, 30, 155-166.	1.2	95
7	Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain. <i>Current Neuropharmacology</i> , 2017, 15, 1156-1173.	1.4	83
8	Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice. <i>Pharmaceutical Research</i> , 2001, 18, 183-190.	1.7	73
9	Heterogeneity in the Rat Brain Vasculature Revealed by Quantitative Confocal Analysis of Endothelial Barrier Antigen and P-Glycoprotein Expression. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 81-92.	2.4	66
10	Clonidine Transport at the Mouse Blood-Brain Barrier by a New H ⁺ Antiporter that Interacts with Addictive Drugs. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1293-1304.	2.4	63
11	Opioid Transport by ATP-Binding Cassette Transporters at the Blood-Brain Barrier: Implications for Neuropsychopharmacology. <i>Current Pharmaceutical Design</i> , 2011, 17, 2829-2842.	0.9	63
12	Apparent lack of Mrp1-mediated efflux at the luminal side of mouse blood-brain barrier endothelial cells. <i>Pharmaceutical Research</i> , 2003, 20, 904-909.	1.7	61
13	Effect of chronic exposure to morphine on the rat blood-brain barrier: focus on the P-glycoprotein. <i>Journal of Neurochemistry</i> , 2008, 107, 647-657.	2.1	60
14	Respiratory toxicity of buprenorphine results from the blockage of P-glycoprotein-mediated efflux of norbuprenorphine at the blood-brain barrier in mice. <i>Critical Care Medicine</i> , 2012, 40, 3215-3223.	0.4	58
15	Immune Quiescence of the Brain Is Set by Astroglial Connexin 43. <i>Journal of Neuroscience</i> , 2015, 35, 4427-4439.	1.7	55
16	Isolation and differential transcriptome of vascular smooth muscle cells and mid-capillary pericytes from the rat brain. <i>Scientific Reports</i> , 2018, 8, 12272.	1.6	55
17	Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P-glycoprotein on a novel verapamil influx carrier. <i>British Journal of Pharmacology</i> , 2016, 173, 497-510.	2.7	50
18	Effects of Selected OATP and/or ABC Transporter Inhibitors on the Brain and Whole-Body Distribution of Glyburide. <i>AAPS Journal</i> , 2013, 15, 1082-1090.	2.2	49

#	ARTICLE	IF	CITATIONS
19	Cannabidiol Increases Proliferation, Migration, Tubulogenesis, and Integrity of Human Brain Endothelial Cells through TRPV2 Activation. <i>Molecular Pharmaceutics</i> , 2019, 16, 1312-1326.	2.3	44
20	Transport of Selected PET Radiotracers by Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2): An In Vitro Screening. <i>Journal of Nuclear Medicine</i> , 2011, 52, 415-423.	2.8	43
21	Functionalized PLA-PEG nanoparticles targeting intestinal transporter PepT1 for oral delivery of acyclovir. <i>International Journal of Pharmaceutics</i> , 2017, 529, 357-370.	2.6	43
22	<i>In Situ</i> Mouse Carotid Perfusion Model: Glucose and Cholesterol Transport in the Eye and Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2008, 28, 1449-1459.	2.4	42
23	Does modulation of organic cation transporters improve pralidoxime activity in an animal model of organophosphate poisoning?*. <i>Critical Care Medicine</i> , 2011, 39, 803-811.	0.4	41
24	Coexistence of Passive and Proton Antiporter-Mediated Processes in Nicotine Transport at the Mouse Blood-Brain Barrier. <i>AAPS Journal</i> , 2013, 15, 299-307.	2.2	41
25	Carrier-Mediated Cocaine Transport at the Blood-Brain Barrier as a Putative Mechanism in Addiction Liability. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu001-pyu001.	1.0	39
26	[18F]FEPPA a TSPO Radioligand: Optimized Radiosynthesis and Evaluation as a PET Radiotracer for Brain Inflammation in a Peripheral LPS-Injected Mouse Model. <i>Molecules</i> , 2018, 23, 1375.	1.7	38
27	The Sarcoglycan complex is expressed in the cerebrovascular system and is specifically regulated by astroglial Cx30 channels. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 9.	1.8	35
28	Transport of Biogenic Amine Neurotransmitters at the Mouse Blood-Retina and Blood-Brain Barriers by Uptake1 and Uptake2. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1989-2001.	2.4	34
29	Immunoregulation at the gliovascular unit in the healthy brain: A focus on Connexin 43. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 1-9.	2.0	33
30	In Situ Transport of Vinblastine and Selected P-glycoprotein Substrates: Implications for Drug-Drug Interactions at the Mouse Blood-Brain Barrier. <i>Pharmaceutical Research</i> , 2004, 21, 1382-1389.	1.7	31
31	Impact of P-glycoprotein at the blood-brain barrier on the uptake of heroin and its main metabolites: behavioral effects and consequences on the transcriptional responses and reinforcing properties. <i>Psychopharmacology</i> , 2014, 231, 3139-3149.	1.5	30
32	In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier. <i>Pharmaceutical Research</i> , 2003, 20, 1607-1611.	1.7	29
33	Pharmacophore-based discovery of inhibitors of a novel drug/proton antiporter in human brain endothelial hCMEC/D3 cell line. <i>British Journal of Pharmacology</i> , 2015, 172, 4888-4904.	2.7	28
34	Discrepancies in the P-glycoprotein-Mediated Transport of 18F-MPPF: A Pharmacokinetic Study in Mice and Non-human Primates. <i>Pharmaceutical Research</i> , 2012, 29, 2468-2476.	1.7	27
35	A polyspecific drug/proton antiporter mediates diphenhydramine and clonidine transport at the mouse blood-retinal barrier. <i>British Journal of Pharmacology</i> , 2015, 172, 4714-4725.	2.7	23
36	Assessment of P-Glycoprotein Transport Activity at the Human Blood-Retina Barrier with (<i>R</i>)- ¹¹ C-Verapamil PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 678-681.	2.8	23

#	ARTICLE	IF	CITATIONS
37	Stability of Bortezomib 1-mg/mL Solution in Plastic Syringe and Glass Vial. <i>Annals of Pharmacotherapy</i> , 2005, 39, 1462-1466.	0.9	22
38	Effect of Subchronic Intravenous Morphine Infusion and Naloxone-Precipitated Morphine Withdrawal on P-gp and Bcrp at the Rat Blood-Brain Barrier. <i>Journal of Pharmaceutical Sciences</i> , 2016, 105, 350-358.	1.6	22
39	Peptide-vector strategy bypasses P-glycoprotein efflux, and enhances brain transport and solubility of paclitaxel. <i>Anti-Cancer Drugs</i> , 2004, 15, 947-954.	0.7	21
40	An Interspecies Molecular and Functional Study of Organic Cation Transporters at the Blood-Brain Barrier: From Rodents to Humans. <i>Pharmaceutics</i> , 2020, 12, 308.	2.0	20
41	Changes in dipole membrane potential at the mouse blood-brain barrier enhance the transport of ^{99m} Tc-Technetium Sestamibi more than inhibiting Abcb1, Abcc1, or Abcg2. <i>Journal of Neurochemistry</i> , 2009, 108, 767-775.	2.1	19
42	Sodium Transporters Are Involved in Lithium Influx in Brain Endothelial Cells. <i>Molecular Pharmaceutics</i> , 2018, 15, 2528-2538.	2.3	19
43	Megalencephalic leukoencephalopathy with subcortical cysts is a developmental disorder of the gliovascular unit. <i>ELife</i> , 2021, 10, .	2.8	19
44	Validation of a simple HPLC-UV method for rifampicin determination in plasma: Application to the study of rifampicin arteriovenous concentration gradient. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 123, 173-178.	1.4	18
45	Characterization of the Blood-Brain Barrier Integrity and the Brain Transport of SN-38 in an Orthotopic Xenograft Rat Model of Diffuse Intrinsic Pontine Glioma. <i>Pharmaceutics</i> , 2020, 12, 399.	2.0	18
46	Acute Morphine Exposure Increases the Brain Distribution of [¹⁸ F]DPA-714, a PET Biomarker of Glial Activation in Nonhuman Primates. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, pyw077.	1.0	16
47	Structure-Activity Relationships in Platelet-Activating Factor. 12. Synthesis and Biological Evaluation of Platelet-Activating Factor Antagonists with Anti-HIV-1 Activity. <i>Journal of Medicinal Chemistry</i> , 2004, 47, 6410-6419.	2.9	15
48	Diphenhydramine as a selective probe to study H ⁺ -antiporter function at the blood-brain barrier: Application to [¹¹ C]diphenhydramine positron emission tomography imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2185-2195.	2.4	15
49	Gender and strain contributions to the variability of buprenorphine-related respiratory toxicity in mice. <i>Toxicology</i> , 2013, 305, 99-108.	2.0	14
50	Optimization and <i>In Vivo</i> Validation of Peptide Vectors Targeting the LDL Receptor. <i>Molecular Pharmaceutics</i> , 2016, 13, 4094-4105.	2.3	14
51	Imaging Probes and Modalities for the Study of Solute Carrier O (SLCO)-Transport Function <i>In Vivo</i> . <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2335-2344.	1.6	14
52	Evaluation of TSPO PET imaging, a marker of glial activation, to study the neuroimmune footprints of morphine exposure and withdrawal. <i>Drug and Alcohol Dependence</i> , 2017, 170, 43-50.	1.6	13
53	Stability of fludrocortisone acetate solutions prepared from tablets and powder. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2003, 55, 209-213.	2.0	12
54	Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-8.	0.4	12

#	ARTICLE	IF	CITATIONS
55	Improvement of epidermal covering on AEC patients with severe skin erosions by PRIMA-1MET/APR-246. <i>Cell Death and Disease</i> , 2020, 11, 30.	2.7	12
56	Stability of oxaliplatin in infusion bags containing 5% dextrose injection. <i>American Journal of Health-System Pharmacy</i> , 2007, 64, 1950-1954.	0.5	11
57	Ibogaine labeling with ^{99m}Tc -tricarbonyl: Synthesis and transport at the mouse blood-brain barrier. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4650-4660.	1.6	11
58	Assessment of practices for suspended oral drugs by tablet crushing in pediatric units. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2020, 157, 175-182.	2.0	11
59	Molecular and Functional Study of Transient Receptor Potential Vanilloid 1-4 at the Rat and Human Blood-Brain Barrier Reveals Interspecies Differences. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 578514.	1.8	11
60	[^{11}C]bexlopatone brain kinetics is not influenced by Bcrp function at the blood-brain barrier: A PET study using Bcrp TGEM knockout rats. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 50, 520-525.	1.9	10
61	Voriconazole topical cream formulation: evidence for stability and antifungal activity. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106083.	1.1	10
62	Astroglial Connexin 43 Deficiency Protects against LPS-Induced Neuroinflammation: A TSPO Brain μPET Study with [^{18}F]FEPPA. <i>Cells</i> , 2020, 9, 389.	1.8	9
63	Maternal ABVD chemotherapy for Hodgkin lymphoma in a dichorionic diamniotic pregnancy: a case report. <i>BMC Pregnancy and Childbirth</i> , 2020, 20, 231.	0.9	9
64	External contamination of antineoplastic drug vials: an occupational risk to consider. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 284-286.	0.5	9
65	Stability of voriconazole injection in 0.9% sodium chloride and 5% dextrose injections. <i>American Journal of Health-System Pharmacy</i> , 2006, 63, 1423-1426.	0.5	8
66	Safety of intrathecal route: focus to methylprednisolone acetate (Depo-Medrol) use. <i>European Spine Journal</i> , 2019, 28, 21-30.	1.0	8
67	Formulation and Stability of Ataluren Eye Drop Oily Solution for Aniridia. <i>Pharmaceutics</i> , 2021, 13, 7.	2.0	8
68	Determination of cisapride and norcisapride in human plasma using high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 1998, 714, 395-398.	1.7	7
69	Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. <i>Drug Delivery and Translational Research</i> , 2018, 8, 536-542.	3.0	7
70	The role of brain barriers in the neurokinetics and pharmacodynamics of lithium. <i>Pharmacological Research</i> , 2021, 166, 105480.	3.1	7
71	Influence of P-Glycoprotein Inhibition or Deficiency at the Blood-Brain Barrier on ^{18}F -2-Fluoro-2-Deoxy-d-glucose (^{18}F -FDG) Brain Kinetics. <i>AAPS Journal</i> , 2015, 17, 652-659.	2.2	6
72	Stability study of oral pediatric idebenone suspensions. <i>Pharmaceutical Development and Technology</i> , 2017, 22, 296-299.	1.1	6

#	ARTICLE	IF	CITATIONS
73	Pharmacophore-Based Discovery of Substrates of a Novel Drug/Proton-Antiporter in the Human Brain Endothelial hCMEC/D3 Cell Line. <i>Pharmaceutics</i> , 2022, 14, 255.	2.0	6
74	Treatment of Painful Palmoplantar Keratoderma Related to Pachyonychia Congenita Using EGFR Inhibitors. <i>Biomedicines</i> , 2022, 10, 841.	1.4	6
75	Treatment of Congenital Afibrinogenemia in a Premature Neonate. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1145-1146.	0.9	5
76	A virtual centralized cytotoxic preparation unit simulation to evaluate the pharmacy staff knowledge. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1187-1194.	0.5	5
77	Stability-Indicating Assay for the Determination of Pentobarbital Sodium in Liquid Formulations. <i>International Journal of Analytical Chemistry</i> , 2015, 2015, 1-6.	0.4	4
78	Stability-Indicating HPLC Assay for Determination of Idebenone in Pharmaceutical Forms. <i>Journal of Analytical Methods in Chemistry</i> , 2015, 2015, 1-5.	0.7	4
79	High brain distribution of a new central nervous system drug candidate despite its P-glycoprotein-mediated efflux at the mouse blood-brain barrier. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 117, 68-79.	1.9	4
80	Retinal and choroidal cancers: Blood-retinal barriers considerations in ocular chemotherapy. , 2020, , 303-335.		4
81	Stability of levamisole oral solutions prepared from tablets and powder. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2005, 8, 322-5.	0.9	4
82	Massive tramadol ingestion resulting in fatal brain injury – a pharmacokinetic study with discussion on the involved mechanisms of toxicity. <i>Clinical Toxicology</i> , 2022, , 1-4.	0.8	4
83	A Rapid Stability-Indicating RP-HPLC Method for the Determination of Betaxolol Hydrochloride in Pharmaceutical Tablets. <i>Analytical Chemistry Insights</i> , 2013, 8, ACI.S11256.	2.7	3
84	Stability of Pentobarbital in Water and Oral Pediatric Suspensions. <i>Annals of Pharmacotherapy</i> , 2016, 50, 245-246.	0.9	3
85	Stability of warfarin sodium flavoured preservative-free oral liquid formulations. <i>European Journal of Hospital Pharmacy</i> , 2018, 25, e98-e101.	0.5	3
86	Occupational risks evaluation in a centralized antineoplastic agent preparation unit. <i>SAGE Open Medicine</i> , 2019, 7, 205031211986697.	0.7	3
87	Ruxolitinib photodegradation mechanisms by theoretical and experimental chemistry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 197, 113983.	1.4	3
88	Modifications of physical and functional integrity of the blood-brain barrier in an inducible mouse model of neurodegeneration. <i>Neuropharmacology</i> , 2021, 191, 108588.	2.0	3
89	Management of sirolimus treatment for tumours associated with Kasabach-Merritt phenomenon. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
90	Stability of Hydrocortisone Preservative-Free Oral Solutions. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2015, 20, 197-202.	0.3	2

#	ARTICLE	IF	CITATIONS
91	Stability of suxamethonium in pharmaceutical solution for injection by validated stability-indicating chromatographic method. <i>Journal of Clinical Anesthesia</i> , 2016, 35, 551-559.	0.7	2
92	Stability of Pentobarbital Hydrogel for Rectal Administration in Pediatric Procedural Sedation. <i>Hospital Pharmacy</i> , 2021, 56, 332-337.	0.4	2
93	Transient Receptor Potential Vanilloid in the Brain Gliovascular Unit: Prospective Targets in Therapy. <i>Pharmaceutics</i> , 2021, 13, 334.	2.0	2
94	Stability of 10-mg/mL and 50-mg/mL ketamine oral solutions. <i>American Journal of Health-System Pharmacy</i> , 2021, 78, 825-831.	0.5	2
95	Stability of doxorubicin combined with RadioselectanR, a contrast agent, for chemoembolization. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2005, 30, 255-258.	0.7	1
96	Stability of Betaxolol Suspensions in Oral Syringes and Glass Bottles. <i>Annals of Pharmacotherapy</i> , 2013, 47, 1237-1238.	0.9	1
97	Stability-Indicating High-Performance Liquid Chromatography Assay for the Determination of Sulthiame in Pharmaceutical Dosage Forms. <i>Analytical Chemistry Insights</i> , 2016, 11, ACI.S38656.	2.7	1
98	Formulation and stability study of hydroxychloroquine sulfate oral suspensions. <i>Pharmaceutical Development and Technology</i> , 2021, 26, 328-334.	1.1	1
99	Stability of pemetrexed diarginine concentrates for solution in vials and diluted in 0.9% sodium chloride and dextrose 5% polyolefin infusion bags. <i>European Journal of Hospital Pharmacy</i> , 2022, 29, 353-358.	0.5	1
100	Stability and Formulation of Erlotinib in Skin Creams. <i>Molecules</i> , 2022, 27, 1070.	1.7	1
101	Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions. <i>International Journal of Pharmaceutical Compounding</i> , 2017, 21, 160-163.	0.0	1
102	Physicochemical Stability Study of Oral Suspension Containing Ruxolitinib in Children with Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Scientific World Journal, The</i> , 2022, 2022, 1-6.	0.8	1
103	Buprenorphine and norbuprenorphine-related respiratory effects in mice: Role of p-glycoprotein transporter. <i>Toxicology Letters</i> , 2011, 205, S184.	0.4	0